Paratek Pharmaceuticals, Inc. announced the appointment of Minnie Baylor-Henry, J.D. to the Board as an independent director, effective as of June 9, 2021. Ms. Baylor-Henry will be a Class I director and will hold office until the 2023 annual meeting of stockholders and until her successor is elected and qualified. The Board has also appointed Ms. Baylor-Henry to the Audit Committee of the Board. Ms. Baylor-Henry is president of B-Henry & Associates. Prior to starting her own firm, Ms. Baylor-Henry held leadership roles with Johnson & Johnson (J&J) including most recently Worldwide Vice-President for Regulatory Affairs for J&J’s Medical Devices & Diagnostics business and was a National Director for Regulatory & Capital Markets Consulting at Deloitte & Touche. Prior to her first tenure at J&J, Ms. Baylor-Henry worked for the U.S. Food & Drug Administration (FDA). She previously served as the Board Chair for the Food and Drug Law Institute (FDLI). Additionally, she served as the President and Chair of the Board for the Drug Information Association (DIA), where she is currently serving as a Fellow. Ms. Baylor-Henry is a Trustee for Howard University, as well as the Chair of the Board of Visitors for Howard University’s College of Pharmacy.